Species distribution and susceptibility profile of yeasts isolated from blood cultures: Results of a multicenter active laboratory-based surveillance study in Argentina;Distribución de especies y perfil de sensibilidad de levaduras aisladas de hemocultivos: Resultados de un estudio multicéntrico de vigilancia de laboratorio en Argentina

Revista Argentina de Microbiologia

Volumn 43, Issue 3, 2011, Pages 176-185

  Córdoba, Susana ^a   Vivot, Walter ^a   Bosco Borgeat, Maria E ^a   Taverna, Constanza ^a   Szusz, Wanda ^a   Murisengo, Omar ^a   Isla, Guillermina ^a   Davel, Graciela ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

Author keywords

Antifungal susceptibility; Fungemia; Yeasts

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARGENTINA; ARTICLE; BLOOD CULTURE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; GALACTOMYCES GEOTRICHUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RHODOTORULA; SACCHAROMYCES CEREVISIAE; SPECIES DISTRIBUTION; TRICHOSPORON; YEAST;

ADULT; ANTIFUNGAL AGENTS; ARGENTINA; CHILD; CROSS INFECTION; DATABASES, FACTUAL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, MULTIPLE, FUNGAL; FEMALE; FUNGEMIA; HUMANS; LABORATORIES, HOSPITAL; MALE; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; SPECIES SPECIFICITY; YEASTS;

EID: 80053069780     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A, and the Barcelona Candidemia Project Study Group. Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
2. Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007; 60: 424-8.
3. Bruder-Nascimento A, Camargo CH, Sugizaki MF, Sadatsune T, Montelli AC, Mondelli AL, Bagagli E. Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital. BMC Res Notes 2010; 3: 1-5.
4. Chagas-Neto TC, Chaves GM, Melo AS, Colombo A. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing. J Clin Microbiol 2009; 47: 1074-81.
5. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Third Edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania 19087-1898 USA, 2008.
6. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Third Informational Supplement. CLSI document M27-S3. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania; 2008.
7. Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta DA, Warnock D, Morgan J. Epidemiology of candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centres. J Clin Microbiol 2006; 44: 2816-23.
8. Córdoba S. Métodos alternativos de laboratorio para la detección de cepas de Cryptococcus neoformans resistentes a los antifúngicos. Tesis de Doctorado en Bacteriología Clínica e Industrial. 2007. INEI ANLIS "Dr. Carlos G. Malbrán" y Universidad Nacional de La Plata.
9. da Cunha MM, dos Santos LP, Dornelas-Ribeiro M, Vermelho AB, Rozental S. Identification, antifungal susceptibility and scanning electron microscopy of a keratinolytic strain of Rhodotorula mucilaginosa: a primary causative agent of onychomycosis. FEMS Immunol Med Microbiol 2009; 55: 396-403.
10. Davel G, Canteros CE. Epidemiological status of mycoses in the Argentine Republic. Rev Argent Microbiol 2007; 39: 28-33.
11. De Pauw B, Walsh TJ, Donnelly JP, Stevens D, Edwards JE, Calandra C, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer GR, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Jan Kullberg B, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
12. EUCAST definitive document E. Def 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 398-405.
13. EUCAST technical Note on fluconazole. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). Clin Microbiol Infect 2008; 14: 193-5.
14. EUCAST technical Note on voriconazole. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). Clin Microbiol Infect 2008; 14: 985-7.
15. Hajjeh RA, Sofair AN, Harrison LH, Lyon M, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE, Thomson Sanza L, Huie S, Fah Yeo S, Brandt ME, Warnock DW. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
16. Horn DL, Neofytos D, Anaissie E, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry. CID 2009; 48: 1695-703.
17. Kalkanci A, Sugita T, Arikan S, Yucesoy M, Ener B, Otag F, Kiraz N, Kustimur S, Sancak B, Evci C, Emektas G. Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients. Med Mycol 2010; 48: 141-6.
18. Khan ZU, Ahmad S, Mokaddas E, Chandy R. Tobacco agar, a new medium for differentiating Candida dubliniensis from Candida albicans. J Clin Microbiol 2004; 42: 4796-8.
19. Kurtzman CP. ed. Kurtzman CP. & Fell JW. The Yeasts: A Taxonomic Study, 4th edition, Elsevier. 1998.
20. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Identification and Susceptibility Profile of Candida fermentati from a Worldwide Collection of Candida guilliermondii Clinical Isolates. J Clin Microbiol 2009; 47: 242-4.
21. Lozano-Chiu M, Nelson PW, Lancaster M, Pfaller MA, Rex JH. Lot-to-lot variability of antibiotic medium 3 when used for susceptibility testing of Candida isolates to amphotericin B. J Clin Microbiol 1997; 35: 270-2.
22. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
23. Möller EM, Bahnweg G, Sandermann H, Geiger HH. A simple and efficient protocol for isolation of high molecular weight DNA from filamentous fungi, fruit bodies, and infected plant tissues. Nucleic Acids Res 1992; 20: 6115-6.
24. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch S. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
25. Panizo MM, Reviákina V, Dolande M, Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol 2009; 47: 137-43.
26. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra T Jr., Edwards JE Jr., Filler SC, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. CID 2009; 48: 503-35.
27. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. In vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. J Clin Microbiol 2008; 46: 150-6.
28. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA, and the SENTRY Participant Group. International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2001; 39: 3254-9.
29. Pfaller MA, Diekema DJ. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin Microbiol Rev 2007; 20: 133-63.
30. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518-21.
31. Pfaller, MA, Diekema DJ, Mendez M, Kibbler C, Erzsbet P, Chang SC, Gibbs DL, Newell VA, and the Global Antifungal Surveillance Group. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J Clin Microbiol 2006; 44: 3551-6.
32. Pincus DH, Orenga S, Chatellier S. Yeast identification-past, present, and future methods. Med Mycol 2007; 45: 97-121.
33. Powderly WG. Current approach to the management of cryptococcal infections. J Infect 2000; 41: 18-22.
34. Rex JH, Cooper CR Jr., Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906-9.
35. Rodero L, Córdoba S, Cahn P, Soria M, Lucarini M, Davel G, Kaufman S, Canteros C, Guelfand L. Time-kill curves for Cryptococcus neoformans isolated from patients with AIDS. Med Mycol 2000; 38: 201-7.
36. Rodero L, Córdoba S, Vivot W, Campo M, Corfield P, Olguín C, Cuirolo A, Soria M, Guelfand L, Canteros CE, Davel G, Red WHONET. Disk diffusion method for fluconazole susceptibility testing of Candida spp. isolates. Rev Argent Microbiol 2006; 38: 155-63.
37. Rodero L, Cuenca-Estrella M, Córdoba S, Cahn P, Davel G, Kaufman S, Guelfand L, Rodríguez-Tudela JL. Transient Fungemia Caused by an Amphotericin B-Resistant Isolate of Candida haemulonii. J Clin Microbiol 2002; 40: 2266-9.
38. Rodero L, Davel G, Soria M, Vivot W, Córdoba S, Canteros CE, Saporiti A y Participantes del Grupo EMIFN. Multicenter study of fungemia due to yeasts in Argentina. Rev Argent Microbiol 2005; 37: 189-95.
39. Rodriguez-Tudela JL, Donnelly JP,. Pfaller MA, Chryssantou E, Warn P, Denning DW, Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M. Statistical Analyses of Correlation between Fluconazole MICs for Candida spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E. Dis. 7.1) and CLSI (M27-A2) J Clin Microbiol 2007; 45: 109-11.
40. Rodríguez-Tudela JL, Martín-Diez F, Cuenca-Estrella M, Rodero L, Carpintero Y, Gorgojo B. Influence of shaking of antifungal susceptibility testing of Cryptococcus neoformans: a comparison of NCCLS Standard M27-A medium, buffered yeast nitrogen base, and RPMI-2 % glucose. Antimicrob Agent Chemoter 2000; 44: 400-4.
41. Santos PE, Córdoba S, Carrillo-Munoz A, Rodero L, Rubeglio E, Soria M. Epidemiología de las fungemias en un hospital pediátrico de alta complejidad. Rev Iberoam Micol 2010; 27: 200-2.
42. Sarvikivi E, Lyytikainen O, Soll DR, Pujol C, Pfaller MA, Richardson M, Koukila-Kähkölä P, Luukkainen P, Saxén H. Emergence of fluconazole resistance in a Candida parap silosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005; 43: 2729-35.
43. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, Morrissey CO, Chen SC; Australian Candidemia Study, Australasian Society for Infectious Diseases. Candidemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65: 1042-51.
44. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520-2.
45. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.